Mission Produce Sets Aggressive Five-Year Targets at Investor Day

What happened

Mission Produce hosted its 2026 Investor Day on October 8, 2026, unveiling five-year financial targets of mid-single-digit organic sales growth and 300 basis points of margin expansion, along with a 2035 ambition to double sales and triple Adjusted EBITDA. Management framed the strategy as designed to deliver high-single-digit to double-digit annual shareholder returns over time, building on its vertically integrated avocado platform and the pending Calavo Growers acquisition. The targets imply EBITDA margins approaching 10-11% by fiscal 2030, significantly above our base-case assumption of ~8% and requiring flawless execution across international farming, distribution, and synergy capture. These announcements come amid ongoing tariff uncertainty, heavy capital spending, high customer concentration, and integration risks that have previously pressured margins. While the roadmap is directionally consistent with the company's narrative as a global avocado consolidator, the magnitude of the targets appears optimistic and will demand visible proof of margin expansion and cash-flow generation.

Implication

Investors should treat the Investor Day targets as management's aspirational roadmap, not a forecast, given the company's historical volatility and exposure to external shocks. Achieving mid-single-digit organic growth and 300 bps margin expansion over five years would require sustained volume gains well above global category growth rates, successful Calavo integration with all $25M in synergies, and resolution of tariff and labor issues without margin erosion. The 2035 ambition to double sales and triple EBITDA implies roughly 7% annual sales growth and 12% EBITDA growth, a pace that appears disconnected from the industry's 1.5-2% volume CAGR and Mission's record of uneven profitability. At the current price of $13.17 (8.3x EV/EBITDA, 25x P/E), the market already discounts a significant improvement; therefore, any disappointment in near-term quarterly results or Calavo regulatory progress could compress the multiple. We maintain our WAIT rating and would look for a pullback toward $11 or concrete evidence of margin expansion before turning constructive.

Thesis delta

The Investor Day targets introduce a more aggressive long-term growth and margin trajectory than our base case, but they are not yet supported by operational data or a clear path to de-risking. Our investment thesis remains unchanged: the stock is fairly valued with significant execution risk, and we see no reason to upgrade without evidence of margin gains or a better entry point. If management begins delivering on these targets in upcoming quarters, we would revisit our valuation.